サマリー

市場展望（MARKET OUTLOOK
トリトンは、世界のアルツハイマー病治療薬・診断薬市場が2022年から2028年にかけて年平均成長率6.98%で成長すると予測しています。
アルツハイマー病（AD）の高い有病率と高齢者人口の増加が、この市場の成長を促進する主な要因です。高齢者層はこの病気の発症リスクが高く、治療薬や診断薬の需要を助長すると予想されます。しかし、政府による厳しい規制や、後発医薬品の臨床試験での失敗が、この産業の成長を妨げています。一方、AD治療のための新しい診断技術の出現は、市場発展のための新たな道筋を生み出しています。
地域別展望
アルツハイマー病の治療薬と診断薬の世界市場は、ヨーロッパ、アジア太平洋地域、ラテンアメリカ、中東・アフリカ、北米にまたがっています。
北米は2021年の世界市場で最大のシェアを占めており、予測期間終了後もそのリードを維持すると予測されます。この地域の市場には、米国やカナダなどの先進国が考えられています。老人人口の増加やアルツハイマー病の負担増などの要因が、北米の市場成長に寄与しています。統計によると、米国では65歳以上の9人に1人がADに罹患しています。このため、アルツハイマー病の新規治療薬や診断薬の開発に対する需要が高まっています。
競合他社の見通し
アルツハイマー病治療薬および診断薬市場に従事している主要なプレーヤーには、Teva Pharmaceutical Industries Ltd、Pfizer Inc、Sun Pharmaceuticals Industries Ltd、Lupin Limited、GE Healthcare、Novartis AG、Eisai Co Ltd、Allergan Plc (acquired by Abbvie)、Siemens Healthineers AG、Biogen Inc、Johnson and Johnson、Baxter International Inc、Zydus Cadila、Amarantus Bioscience Holdings Inc、Cognoptix Inc、Merck and Co、Eli Lilly & Companyおよび F. Hoffmann-La Roche AG等があります。
Allergan Plc（Abbieが買収）は、バイオシミラー医薬品、特殊ブランド医薬品、一般用医薬品の開発、製造、販売、流通を行う医薬品業界のリーディングカンパニーです。同社は、様々な新製品の上市や承認の結果、製品ポートフォリオを強化しています。製品の一つであるNAMZARICは、中等度から重度のアルツハイマー病の症状の治療を支援するものです。2013年に設立された同社は、世界中で1,200人以上の従業員を擁しています。米国、中国、カナダ、インドをはじめ、欧州、中東、中南米、東南アジアの急成長市場など、多くの国々で事業を展開しています。2020年5月にAbbVie社に買収された。

ページTOPに戻る

目次

TABLE OF CONTENTS
1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY INSIGHTS
2.3.1. USAGE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND FOR PERSONALIZED MEDICINES
2.4. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S FIVE FORCES ANALYSIS
2.6. MARKET ATTRACTIVENESS MATRIX
2.7. VENDOR SCORECARD
2.8. INDUSTRY COMPONENTS
2.8.1. RESEARCH & DEVELOPMENT (R & D)
2.8.2. RAW MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT LAUNCHES
2.10.3. CONTRACTS & AGREEMENTS
2.10.4. INVESTMENTS & EXPANSIONS
2.11. MARKET DRIVERS
2.11.1. PREVALENCE OF ALZHEIMER’S DISEASE
2.11.2. RISE IN THE ELDERLY POPULATION
2.12. MARKET CHALLENGES
2.12.1. FAILURE OF LATE-STAGE DRUGS
2.12.2. STRINGENT GOVERNMENT REGULATIONS
2.13. MARKET OPPORTUNITIES
2.13.1. EMERGENCE OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING NUMBER OF PIPELINE DRUGS
3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS
3.1. BY DRUG TYPE
3.1.1. MARKETED DRUGS
3.1.2. PIPELINE DRUGS
3.2. BY DISEASE STAGE
3.2.1. LATE STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL STAGE
3.3. BY GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR PUNCTURE TEST
4.2. POSITRON EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC RESONANCE IMAGING
4.5. COMPUTED TOMOGRAPHY
4.6. BLOOD TEST
4.7. OTHER DIAGNOSTICS
5. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK
5.1. NORTH AMERICA
5.1.1. MARKET BY THERAPEUTICS
5.1.1.1. MARKET BY DRUG TYPE
5.1.1.2. MARKET BY DISEASE STAGE
5.1.1.3. MARKET BY GENERIC & BRANDED
5.1.2. MARKET BY DIAGNOSTICS
5.1.3. COUNTRY ANALYSIS
5.1.3.1. UNITED STATES
5.1.3.2. CANADA
5.2. EUROPE
5.2.1. MARKET BY THERAPEUTICS
5.2.1.1. MARKET BY DRUG TYPE
5.2.1.2. MARKET BY DISEASE STAGE
5.2.1.3. MARKET BY GENERIC & BRANDED
5.2.2. MARKET BY DIAGNOSTICS
5.2.3. COUNTRY ANALYSIS
5.2.3.1. UNITED KINGDOM
5.2.3.2. GERMANY
5.2.3.3. FRANCE
5.2.3.4. ITALY
5.2.3.5. SPAIN
5.2.3.6. REST OF EUROPE
5.3. ASIA-PACIFIC
5.3.1. MARKET BY THERAPEUTICS
5.3.1.1. MARKET BY DRUG TYPE
5.3.1.2. MARKET BY DISEASE STAGE
5.3.1.3. MARKET BY GENERIC & BRANDED
5.3.2. MARKET BY DIAGNOSTICS
5.3.3. COUNTRY ANALYSIS
5.3.3.1. CHINA
5.3.3.2. JAPAN
5.3.3.3. INDIA
5.3.3.4. SOUTH KOREA
5.3.3.5. ASEAN COUNTRIES
5.3.3.6. AUSTRALIA AND NEW ZEALAND
5.3.3.7. REST OF ASIA-PACIFIC
5.4. LATIN AMERICA
5.4.1. MARKET BY THERAPEUTICS
5.4.1.1. MARKET BY DRUG TYPE
5.4.1.2. MARKET BY DISEASE STAGE
5.4.1.3. MARKET BY GENERIC & BRANDED
5.4.2. MARKET BY DIAGNOSTICS
5.4.3. COUNTRY ANALYSIS
5.4.3.1. BRAZIL
5.4.3.2. MEXICO
5.4.3.3. REST OF LATIN AMERICA
5.5. MIDDLE EAST AND AFRICA
5.5.1. MARKET BY THERAPEUTICS
5.5.1.1. MARKET BY DRUG TYPE
5.5.1.2. MARKET BY DISEASE STAGE
5.5.1.3. MARKET BY GENERIC & BRANDED
5.5.2. MARKET BY DIAGNOSTICS
5.5.3. COUNTRY ANALYSIS
5.5.3.1. UNITED ARAB EMIRATES
5.5.3.2. TURKEY
5.5.3.3. SAUDI ARABIA
5.5.3.4. SOUTH AFRICA
5.5.3.5. REST OF MIDDLE EAST & AFRICA
6. COMPETITIVE LANDSCAPE
6.1. BAXTER INTERNATIONAL INC
6.2. F. HOFFMANN-LA ROCHE AG
6.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS AG
6.5. PFIZER INC
6.6. SIEMENS HEALTHINEERS AG
6.7. AMARANTUS BIOSCIENCE HOLDINGS INC
6.8. EISAI CO LTD
6.9. ELI LILLY & COMPANY
6.10. LUPIN LIMITED
6.11. MERCK AND CO
6.12. BIOGEN INC
6.13. COGNOPTIX INC
6.14. GE HEALTHCARE
6.15. JOHNSON AND JOHNSON
6.16. SUN PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS CADILA
7. METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE
7.2. SOURCES OF DATA
7.3. RESEARCH METHODOLOGY

TABLE LIST
TABLE 1: MARKET ATTRACTIVENESS MATRIX
TABLE 2: VENDOR SCORECARD
TABLE 3: KEY STRATEGIC DEVELOPMENTS
TABLE 4: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 16: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 21: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 27: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 32: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 33: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 37: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 38: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 39: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

FIGURE LIST
FIGURE 1: PORTER’S FIVE FORCES ANALYSIS
FIGURE 2: KEY IMPACT ANALYSIS
FIGURE 3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY COMPONENTS
FIGURE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021 & 2028 (IN %)
FIGURE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)
FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)
FIGURE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN %)
FIGURE 10: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)
FIGURE 11: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)
FIGURE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 & 2028 (IN %)
FIGURE 14: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE 17: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)
FIGURE 18: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 19: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 20: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)
FIGURE 21: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 22: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)
FIGURE 24: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)
FIGURE 25: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 28: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 31: SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 36: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 38: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: MEXICO ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 44: SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 45: TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 46: SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 47: REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

ページTOPに戻る

図表リスト

TABLE LIST
TABLE 1: MARKET ATTRACTIVENESS MATRIX
TABLE 2: VENDOR SCORECARD
TABLE 3: KEY STRATEGIC DEVELOPMENTS
TABLE 4: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 16: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 21: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 27: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 32: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 33: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 37: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)
TABLE 38: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)
TABLE 39: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)